Skip to main content
S&P 5007,591.70-0.58%DOW52,064.10-0.60%NASDAQ26,081.72-0.65%BTC$76,818.00-1.50%ETH$2,454.88-0.50%GOLD$4,381.40-0.59%OIL$99.30-3.10%
Smart Investors Daily
CL

NASDAQ · CLNN

Clene Inc.

Healthcare · Biotechnology

$3.65

Down-$0.07 (-1.88%)

Updated Sep 11, 2026, 11:39 AM

SID Score

3.2/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
64.85M
P/E ratio
-2.23
Dividend yield
0.00%
52-week range
$3.48 – $8.67
Volume
113.16K
Avg. volume
192.2K

Price performance

CLNN price history

1M range · 0 trading sessions · Daily adjusted prices

CLNN does not have enough price history for the selected period.

Data unavailable

Market data is busy. Please try again shortly.

Latest CLNN news

The latest Smart Investors Daily articles mentioning CLNN.

Stock researchCompany · Overview

CLNN research

Overview

Company profile and research snapshot.

Company profile

Clene Inc is a clinical-stage pharmaceutical company pioneering the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. It is focused on the development of therapeutics for neurodegenerative diseases. It developed an electro-crystal-chemistry drug development platform that enables the production of concentrated, stable, clean-surfaced nanocrystal suspensions. It operates in one segment the development and commercialization of dietary supplements (Supplements). Products includes CNM-Au8, CNM-ZnA, CNM-AgZn17, rMetx, KHC46.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$50.00
Implied upside
—
Analysts
—
CLNN recent ratings
DateFirmRatingTarget
May 4, 2026HC Wainwright & Co.Buy—
May 4, 2026D. Boral CapitalBuy—
Mar 13, 2026Canaccord GenuityBuy—
Mar 12, 2026D. Boral CapitalBuy—
Jan 9, 2026D. Boral CapitalBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 3, 2026

Clene to Present at Upcoming September Investor Conferences

SALT LAKE CITY, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) today announced that management will present at the 2026 Cantor Global Healthcare Conference and at the H.C. Wainwright 28th Annual Global Investment Conference and host 1x1 investor meetings at both conferences. 2026 Cantor Global Healthcare ConferenceDate: September 9, 2026Time of Presentation: 9:10am ETLocation: New York, NYFormat: Presentation and 1x1 meetings1x1 Meetings: Please contact your Cantor representativeWe

globenewswire.com · Dec 9, 2025

Presenting on Emerging Growth Conference 88 Day 1 on December 10; Register to live stream

MIAMI, Dec. 09, 2025 (GLOBE NEWSWIRE) -- EmergingGrowth. com a leading independent small cap media portal announces the schedule of the 88th Emerging Growth Conference on December 10 and 11, 2025. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products and services, focused strategy, execution, and the overall potential for long-term growth.

Yahoo · Dec 3, 2025

Clene Announces Statistically Significant ALS Biomarker Results Supporting Accelerated Approval Pathway for CNM-Au8®

FDA recommended biomarker analyses show statistically significant reductions in NfL and GFAP in participants treated with CNM-Au8Biomarker improvements are strongly associated with longer survival, reinforcing CNM-Au8’s potential disease modifying activityCompany has requested a Type C meeting in the first quarter of 2026 to present the newly completed analyses supporting a planned NDA submission under the accelerated approval pathwayClene is hosting an investor webcast today at 8:30 am ET SALT

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By